NCT05217212View on ClinicalTrials.gov

Do Markers of Systemic Inflammatory Response and Tumor Metabolism Indicate Radioresistance in Head and Neck Cancer?

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
RADIATION

Radiochemotherapy

Primary radiotherapy of the primary tumor and nodal basin with curative intent with or without concomitant chemotherapy with cisplatin, carboplatin, or cetuximab weekly.

Trial Locations (1)

Unknown

RECRUITING

Department of Otorhinolaryngology - Head and Neck Surgery, Cantonal Hospital Lucerne, Lucerne

All Listed Sponsors
collaborator

Universität Luzern

OTHER

lead

Luzerner Kantonsspital

OTHER